Pharmagreen Biotech Inc Stock Price, News & Analysis

Pharmagreen Biotech, Inc. (OTCQB: PHBI) announces progress on its acquisition of Long Valley Farms, making a significant payment to fully clear a 12-acre property. This move secures the land for its cannabis cultivation operations and licenses under California's legacy system amidst impending regulatory changes. The acquisition aligns with Pharmagreen’s vertical growth strategy to monetize its proprietary cannabis tissue culture technology, Chibafreen, while the company continues to apply for additional cannabis licenses and construct IoT greenhouses.

Pharmagreen Biotech, Inc. (OTCQB: PHBI) announced a memorandum of understanding to acquire Long Valley Farms LLC, a California cannabis company. This acquisition encompasses land, infrastructure, and a cannabis cultivation license. It aims to leverage Pharmagreen's proprietary cannabis tissue culture technology, Chibafreen, to generate revenue. Long Valley Farms plans to apply for additional cannabis licenses immediately. The MOU is an affirmation of the prior agreement from July 2021. CEO Ethan Styles emphasizes the strategic potential of this acquisition to enhance market share in California's evolving cannabis industry.

Pharmagreen Biotech (OTCQB: PHBI) confirmed a memorandum of understanding (MOU) to acquire California-based Long Valley Farms LLC, including its land, infrastructure, and cannabis cultivation license. This strategic acquisition aims to leverage Pharmagreen’s proprietary cannabis tissue culture technology, Chibafreen, into realized revenue. Long Valley Farms plans to apply for multiple cannabis licenses in California. This MOU expands upon a prior agreement from July 2021, committing Pharmagreen to cover ongoing operational costs related to Long Valley Farms.

Pharmagreen Biotech (OTCQB: PHBI) announced the approval of its application to up-list from OTC Pinks to OTCQB, effective December 20, 2021. The OTCQB is a notable marketplace for entrepreneurial companies emphasizing transparency and quality trading experiences. CEO Peter Wojcik highlighted that this upgrade is crucial for investor confidence, especially in the complex cannabis industry. Additionally, Pharmagreen initiated a crowdfunding campaign on DealMaker, offering shares under a Regulation A offering qualified in September 2021, further expanding its capital-raising options.

Pharmagreen Biotech Inc. (OTCQB: PHBI) has successfully gained approval for its application to the OTCQB Venture Market, enhancing its visibility among investors. The OTCQB is designed for growth-oriented companies, ensuring transparency and compliance through rigorous standards. CFO Peter Wojcik emphasized the importance of transparency in the cannabis industry. Additionally, Pharmagreen has initiated a crowdfunding campaign on DealMaker to raise up to $7.5 million, selling units at $0.025 each for the acquisition of a cannabis company and the construction of a state-of-the-art greenhouse.

Pharmagreen Biotech, Inc. (OTC PINK: PHBI) is advancing its proprietary cannabis tissue culture technology into a revenue-generating operation, as announced by CEO Peter Wojcik. The company is nearing completion of its application for an up-listing to the OTCQB Venture Market, enhancing compliance and transparency for investors. Additionally, Pharmagreen is finalizing an acquisition of a California cannabis enterprise, including essential licenses and infrastructure. Regular updates will be provided to stakeholders as the company transitions its technology into a source of recurring revenue.

Pharmagreen Biotech (OTC PINKS: PHBI) released a management update from CEO Peter Wojcik on its strategy to monetize its proprietary Chibafreen tissue culture technology. This technology aims to enhance cannabis production efficiency while maintaining genetic purity. Wojcik emphasizes the importance of a strong executive team, including COO Dr. Fawzia Afreen and CFO Terry Kwan, in executing the business strategy. The company plans to provide further updates to shareholders and aims to establish Chibafreen as an industry standard in cannabis cultivation.

Pharmagreen Biotech, Inc. (OTC PINK: PHBI) released a management update from CEO Peter Wojcik outlining the company's strategy to monetize its proprietary tissue culture technology, Chibafreen. This technology aims to enhance scalability and genetic purity in cannabis cultivation. The executive team, including COO Dr. Fawzia Afreen and CFO Terry Kwan, is positioned to drive growth and transition Chibafreen into a recurring revenue source. Future updates to shareholders are anticipated to further clarify the strategy and execution.

Pharmagreen Biotech (OTC Pink: PHBI) has announced a strategic update from CEO Peter Wojcik regarding the company's plans to leverage its proprietary Chibafreen tissue culture process for revenue generation. The process aims to supply genetically identical and disease-free cannabis starter plantlets, enhancing scalability in the cannabis industry. A 12,000 square foot IoT-enabled greenhouse in Northern California is central to this strategy, potentially generating $10 million annually in cash flow. Pharmagreen anticipates revenue generation starting in 2022, with further growth expected over five years.